MARKET

FGEN

FGEN

Fibrogen Inc
NASDAQ
13.77
+0.50
+3.77%
After Hours: 13.77 0 0.00% 16:15 10/04 EDT
OPEN
13.42
PREV CLOSE
13.27
HIGH
13.80
LOW
13.21
VOLUME
777.47K
TURNOVER
0
52 WEEK HIGH
16.91
52 WEEK LOW
7.81
MARKET CAP
1.29B
P/E (TTM)
-5.8229
1D
5D
1M
3M
1Y
5Y
SHLS, FORM, HOWL and VWE are among after hour movers
Gainers: Shoals Technologies Group (SHLS) +6.2%. FormF...
Seekingalpha · 09/13 21:25
Short Volatility Alert: FibroGen, Inc.
On Tuesday, shares of FibroGen, Inc. (NASDAQ: FGEN) experienced volatile short activity. After the activity, the stock price went down -4.38% to $12.87. The overall sentiment for FGEN has been Bearish.
Benzinga · 08/31 15:18
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Benzinga · 08/26 23:52
FibroGen completes patient enrollment for Roxadustat to treat anemia in patients
FibroGen (NASDAQ:FGEN) <a href="https://seekingalpha.com/pr/189180...
Seekingalpha · 08/26 13:51
BRIEF-Fibrogen Completes Patient Enrollment In Matterhorn, Phase 3 Clinical Study Of Roxadustat
BRIEF-Fibrogen Completes Patient Enrollment In Matterhorn, Phase 3 Clinical Study Of Roxadustat
Reuters · 08/26 11:12
FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)
- 141 MDS Patients Enrolled -- Topline Data Anticipated 1H:2023 - SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for tre...
GlobeNewswire · 08/26 11:00
FibroGen Completes Patient Enrollment for Phase 3 Study of Anemia Drug Candidate
FibroGen Completes Patient Enrollment for Phase 3 Study of Anemia Drug Candidate
MT Newswires · 08/26 07:14
How Much Of FibroGen, Inc. (NASDAQ:FGEN) Do Institutions Own?
Every investor in FibroGen, Inc. ( NASDAQ:FGEN ) should be aware of the most powerful shareholder groups. Insiders...
Simply Wall St. · 08/09 10:30
More
About FGEN
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of therapeutics. It applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes. It also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. The Company is also enrolling patients in its two Phase III trials of pamrevlumab patients.

Webull offers kinds of FibroGen Inc stock information, including NASDAQ:FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.